Concepedia

Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn’s Disease: A Retrospective Study From 2 Referral Centers

Pauline Rivière, C Kanters, Gauthier Pellet, Alexander Ni, Marianne Hupé, Nesrine Aboulhamid, Florian Poullenot, Alain Bitton, Frank Zerbib, Péter L. Lakatos,

Inflammatory Bowel Diseases · 2022 · 17 citations · 15 references

DOI

Abstract

This retrospective real-world data suggest that an anti-TNF agent as a first-line biological therapy is associated with higher rates of response at 3 months than ustekinumab in patients with CD.

References

15

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein et al. · The Lancet · 2002 · 4.1K citations

, , +5

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management

Fernando Gomollón, Vito Annese, Herbert Tilg et al. · Journal of Crohn s and Colitis · 2016 · 2K citations · Full text

, , +12

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Brian G. Feagan, William J. Sandborn, Christopher Gasink et al. · New England Journal of Medicine · 2016 · 1.7K citations · Full text

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases

Julien Kirchgesner, Magali Lemaître, Fabrice Carrat et al. · Gastroenterology · 2018 · 572 citations · Full text

, , +10

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Magali Lemaître, Julien Kirchgesner, A. Rudnichi et al. · JAMA · 2017 · 546 citations · Full text